CPEB3: A Potential Drug Target and Biomarker (G22849)

Target Name: CPEB3

NCBI ID: G22849

CPEB3

CPEB3: A Potential Drug Target and Biomarker

Cytoplasmic polyadenylation element binding protein 3 (CPEB3) is a protein that plays a crucial role in the regulation of gene expression in various organisms, including humans. It is a member of the poly(ADP-ribose) polymerase (PARP) family, which is known for its role in repairing damaged DNA in response to various cellular stressors, such as DNA damage and aging. CPEB3 is highly conserved across various species and has been identified as a potential drug target in the pharmaceutical industry.

The PARP family of proteins consists of three isoforms:PARP1, PARP2, and PARP3. These proteins share a conserved catalytic core and a similar structure, but differ in their N-terminal and C-terminal regions. CPEB3 is the latest addition to the PARP family and is known for its unique structure and function.

CPEB3's Unique Structure and Function

CPEB3 is a 14-kDa protein that contains 115 amino acid residues. It has a characteristic linear molecular structure with a calculated pI of 9.97. CPEB3 is predominantly monomeric and has a unique N-terminal region that contains a conserved catalytic core and a zinc finger domain. The zinc finger domain is responsible for CPEB3's unique stability and functions as a protein-protein interaction partner.

CPEB3's unique structure and function are evident from its purification and biochemical characterization. CPEB3 can be expressed and purified from various sources, including bacteria, yeast, and mammalian cells. The protein exhibits a strong catalytic activity, as demonstrated by its ability to catalyze the polymerization of poly(ADP-ribose) in the absence of nucleotides. Additionally, CPEB3 has been shown to interact with various protein partners, including other PARP isoforms, AP-1, and cyclin D1.

CPEB3's Potential as a Drug Target

CPEB3's unique structure and function make it an attractive target for drug development. The PARP family of proteins has been implicated in various cellular processes, including DNA repair, cell division, and apoptosis. Therefore, drugs that target CPEB3 or its interacting partners may have a wide range of potential therapeutic applications.

One of the potential benefits of targeting CPEB3 is its involvement in the regulation of gene expression. As a protein that plays a crucial role in the regulation of gene expression, CPEB3 may be involved in the regulation of various cellular processes, including cell growth, apoptosis, and DNA repair. Therefore, drugs that target CPEB3 may have therapeutic applications in various diseases, including cancer, neurodegenerative diseases, and aging.

Another potential benefit of targeting CPEB3 is its involvement in DNA repair processes. DNA repair is a critical process that ensures the stability of genetic information and protects against various forms of damage, including DNA damage caused by mutations and errors. CPEB3 is involved in the regulation of DNA repair processes, which may make it a potential target for drugs that promote DNA repair and prevent DNA damage.

CPEB3's Potential as a Biomarker

CPEB3 may also be used as a biomarker for various diseases. Its unique structure and function make it an ideal candidate for use as a protein biomarker. CPEB3 has been shown to be expressed in various biological samples, including blood, saliva, and urine, which may make it a useful biomarker for various diseases.

One of the potential applications of CPEB3 as a biomarker is its involvement in the regulation of gene expression. As previously mentioned, CPEB3 plays

Protein Name: Cytoplasmic Polyadenylation Element Binding Protein 3

Functions: Sequence-specific RNA-binding protein which acts as a translational repressor in the basal unstimulated state but, following neuronal stimulation, acts as a translational activator (By similarity). In contrast to CPEB1, does not bind to the cytoplasmic polyadenylation element (CPE), a uridine-rich sequence element within the mRNA 3'-UTR, but binds to a U-rich loop within a stem-loop structure (By similarity). Required for the consolidation and maintenance of hippocampal-based long term memory (By similarity). In the basal state, binds to the mRNA 3'-UTR of the glutamate receptors GRIA2/GLUR2 mRNA and negatively regulates their translation (By similarity). Also represses the translation of DLG4, GRIN1, GRIN2A and GRIN2B (By similarity). When activated, acts as a translational activator of GRIA1 and GRIA2 (By similarity). In the basal state, suppresses SUMO2 translation but activates it following neuronal stimulation (By similarity). Binds to the 3'-UTR of TRPV1 mRNA and represses TRPV1 translation which is required to maintain normal thermoception (By similarity). Binds actin mRNA, leading to actin translational repression in the basal state and to translational activation following neuronal stimulation (By similarity). Negatively regulates target mRNA levels by binding to TOB1 which recruits CNOT7/CAF1 to a ternary complex and this leads to target mRNA deadenylation and decay (PubMed:21336257). In addition to its role in translation, binds to and inhibits the transcriptional activation activity of STAT5B without affecting its dimerization or DNA-binding activity. This, in turn, represses transcription of the STAT5B target gene EGFR which has been shown to play a role in enhancing learning and memory performance (PubMed:20639532). In contrast to CPEB1, CPEB2 and CPEB4, not required for cell cycle progression (PubMed:26398195)

The "CPEB3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPEB3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets